See more : Sembcorp Industries Ltd (U96.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Bioptik Technology Incorporation (4161.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bioptik Technology Incorporation, a leading company in the Healthcare industry within the Healthcare sector.
- Savannah Resources Plc (SAV.L) Income Statement Analysis – Financial Results
- Austin Engineering Limited (AUSTF) Income Statement Analysis – Financial Results
- Tastemaker Acquisition Corp. (TMKR) Income Statement Analysis – Financial Results
- Tilray Brands, Inc. (TLRY) Income Statement Analysis – Financial Results
- NioCorp Developments Ltd. (NB) Income Statement Analysis – Financial Results
Bioptik Technology Incorporation (4161.TWO)
About Bioptik Technology Incorporation
Bioptik Technology Incorporation engages in the production and sale of medical devices and reagents worldwide. It offers EasyMate blood glucose monitoring systems; blood glucose/cholesterol/uric acid monitoring systems and its strips; and hyaluronic acid skin care products. The company also provides skin care products and dietary supplements, as well as biodiesel products. Bioptik Technology Incorporation was founded in 1999 and is based in Zhunan, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 828.50M | 767.75M | 737.89M | 485.60M | 566.42M |
| Cost of Revenue | 588.96M | 590.29M | 574.35M | 402.44M | 417.82M |
| Gross Profit | 239.54M | 177.46M | 163.55M | 83.16M | 148.61M |
| Gross Profit Ratio | 28.91% | 23.11% | 22.16% | 17.12% | 26.24% |
| Research & Development | 71.47M | 58.30M | 48.94M | 50.15M | 68.63M |
| General & Administrative | 57.37M | 60.74M | 58.20M | 55.07M | 0.00 |
| Selling & Marketing | 20.45M | 19.16M | 20.96M | 21.71M | 0.00 |
| SG&A | 77.83M | 79.90M | 79.17M | 76.78M | 81.45M |
| Other Expenses | 0.00 | 28.57M | -9.59M | -16.84M | 0.00 |
| Operating Expenses | 149.29M | 138.20M | 128.11M | 126.92M | 150.08M |
| Cost & Expenses | 738.55M | 728.49M | 702.45M | 529.36M | 567.89M |
| Interest Income | 10.70M | 3.95M | 1.29M | 3.85M | 8.62M |
| Interest Expense | 11.00M | 9.19M | 7.82M | 8.47M | 9.76M |
| Depreciation & Amortization | 34.72M | 33.47M | 36.98M | 37.75M | 41.11M |
| EBITDA | 152.18M | 105.47M | 64.41M | -17.48M | 50.57M |
| EBITDA Ratio | 18.37% | 13.71% | 8.69% | -3.91% | 8.93% |
| Operating Income | 90.25M | 71.78M | 27.15M | -56.76M | -1.47M |
| Operating Income Ratio | 10.89% | 9.35% | 3.68% | -11.69% | -0.26% |
| Total Other Income/Expenses | 16.22M | -8.97M | -7.53M | -19.93M | 1.17M |
| Income Before Tax | 106.47M | 62.81M | 19.62M | -63.69M | -305.00K |
| Income Before Tax Ratio | 12.85% | 8.18% | 2.66% | -13.12% | -0.05% |
| Income Tax Expense | 21.89M | 15.78M | -938.00K | -1.48M | -317.00K |
| Net Income | 85.71M | 48.50M | 22.59M | -59.99M | 5.25M |
| Net Income Ratio | 10.35% | 6.32% | 3.06% | -12.35% | 0.93% |
| EPS | 1.68 | 1.00 | 0.45 | -1.18 | 0.10 |
| EPS Diluted | 1.67 | 1.00 | 0.45 | -1.18 | 0.10 |
| Weighted Avg Shares Out | 50.93M | 50.69M | 50.68M | 50.68M | 50.68M |
| Weighted Avg Shares Out (Dil) | 51.32M | 50.93M | 50.76M | 50.68M | 50.69M |
Source: https://incomestatements.info
Category: Stock Reports